Telix Pharmaceuticals (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals (ASX: TLX)
Latest News
Value Investing
2 ASX 200 shares down 30% or more that could be a new years buy
Healthcare Shares
Telix shares storm higher on big US and China news
Share Market News
These are the 10 most shorted ASX shares
Share Market News
Telix Pharmaceuticals in focus with China trial success and FDA updates
Healthcare Shares
Bell Potter names the best ASX healthcare shares to buy in 2026
Healthcare Shares
Why is everyone talking about Telix shares this week?
Opinions
5 ASX shares I'd buy with $10,000 this week
Healthcare Shares
Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?
Healthcare Shares
Which drug company could pile on almost 30% in gains according to RBC Capital?
Share Market News
These are the 10 most shorted ASX shares
Growth Shares
These exciting ASX 200 growth shares could rise 60% to 100% in 2026
Share Market News
These are the 10 most shorted ASX shares
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
